Headquartered in Santa Barbara, California, Sientra is a diversified global medical aesthetics company and a leading partner to aesthetic physicians. The Company offers a suite of products designed to make a difference in patients' lives by enhancing their body image, growing their self-esteem, and restoring their confidence. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s Breast Products Segment includes its OPUS® breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, and BIOCORNEUM® the #1 performing, preferred and recommended scar gel of plastic surgeons(*). The Company’s miraDry Segment, comprised of its miraDry® system, is approved for sale in over 56 international markets and is the only non-surgical, FDA-cleared device indicated for the permanent reduction of underarm sweat and hair and may also reduce odor.

Nasdaq: SIEN

Stock Quote: NASD

$4.39 -0.21
Volume 570,586
Previous Close 4.60
Intraday High 4.62
Intraday Low 4.30
Pricing delayed 20 minutes
Price Change % Change -4.56% 52 Week High 8.23 52 Week Low 1.00 Today's Open 4.56 Jan 15, 2021 04:00 PM

Investor Contact

Sientra Investor Relations